secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-021152
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical reports Q4 revenue $62.2M (+25% YoY), FY2023 $187.1M (+32%); guides FY2024 $220-225M
--------------------------------------------------------------------------------

- Q4 2023 revenue $62.2M, up 25% YoY; full-year revenue $187.1M, up 32%, above guidance of $182-186M.
- Q4 net loss ($6.3M) ($0.10/share); full-year net loss ($49.5M) ($0.81/share); adjusted net loss same.
- Active surgeons reached 2,855 (+20% YoY); direct sales reps 227 (+35% YoY).
- FY2024 revenue guidance $220-225M (18-20% growth); expects ~50% improvement in Adjusted EBITDA.
- Launched SpeedPlate, Micro-Lapiplasty, Hammertoe Fixation; patent portfolio 57 granted US patents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017024021152/0000950170-24-021152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017024021152/tmci-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-021152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer